This result, together with the direct correlations demonstrated between high DOT1L levels in tumors, poor disease prognosis, and worse overall and relapse-free survival (Cho et al., 2015; Nassa et al., 2019), suggests the importance of this enzyme in BC and its eligibility as a promising therapeutic target against these neoplasms. The gene discussed is DOT1L; the disease is breast cancer.